Study Title: Randomized Phase II study of the Addition of Targeted Therapeutic Agents to Tafasitamab-based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-cell Lymphoma
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Hess, Brian, at hessbr@musc.edu.Study Coordinator, Mendiola, Hannah, at mendiola@musc.edu.Trial opened at the following institutions: Medical University of South Carolina